---

ASRA Guidelines for Central Neuroaxial Blockade (CNB) in Patients on Anticoagulants

MD Anaesthesiology Examination Notes

---

1. INTRODUCTION & BACKGROUND

• The American Society of Regional Anesthesia and Pain Medicine (ASRA) has published evidence-based guidelines on the use of neuraxial techniques in anticoagulated patients. The current edition is the Fifth Edition (2022, updated 2025).
• The primary concern is spinal epidural hematoma (SEH) — a rare but catastrophic complication causing cord compression, permanent neurological deficit, and paraplegia.
• Incidence of SEH: ~1 in 150,000 epidurals and ~1 in 220,000 spinal anaesthetics in general surgical populations; higher in elderly women with hip fractures (up to 1 in 22,000).
• Because SEH is rare, most recommendations are Grade C/expert opinion; RCTs are not feasible.
• ASRA guidelines are based on pharmacokinetic principles: recommended time intervals allow 97% drug elimination (5 half-lives for therapeutic dosing; 2 half-lives for prophylactic dosing).

---

2. GENERAL ASRA PRINCIPLES

1. Timing of needle/catheter insertion and removal must reflect the pharmacokinetic properties of the specific anticoagulant.
2. Frequent neurological monitoring is mandatory during neuraxial analgesia.
3. Concurrent use of multiple anticoagulants (e.g., LMWH + NSAIDs + antiplatelet) synergistically increases bleeding risk — avoid combinations.
4. Analgesic regimens should be tailored to facilitate neurological monitoring — dilute local anaesthetic preferred.
5. Neurological monitoring may need to continue 24 hours after catheter removal in high-risk patients.
6. In traumatic or difficult needle placement, consider delaying surgery 24 hours to observe.
7. Unexplained back pain, new/progressive neurological deficit, or bladder/bowel dysfunction mandates urgent MRI and surgical decompression — decompression within 8 hours gives best prognosis.

---

3. DRUG-SPECIFIC RECOMMENDATIONS

3.1 Warfarin (Vitamin K Antagonist)

---

3.2 Unfractionated Heparin (UFH)

Subcutaneous Prophylactic UFH (5000 U BID)

• No contraindication to neuraxial technique
• Give heparin injection after the block to reduce hematoma risk
• Risk increased in debilitated patients and after prolonged therapy

Subcutaneous UFH (5000 U TID or higher)

• 5000 U TID is now permitted (new in ASRA 5th Ed) but timing of needle placement and catheter removal relative to dose must be carefully coordinated
• For doses > 10,000 U/dose SC or > 20,000 U total daily: neuraxial block 24 hours after last SC dose + assess coagulation status

Intravenous (Therapeutic) UFH Infusion

---

3.3 Low Molecular Weight Heparin (LMWH)

The introduction of LMWH in North America in 1993 triggered a marked rise in SEH cases, prompting current guidelines.

• Post-block first prophylactic dose: ≥ 12 hours after needle placement
• Post-block first therapeutic dose: ≥ 24 hours after needle placement
• Catheter + LMWH: Indwelling catheter acceptable only with once-daily prophylactic dosing; twice-daily therapeutic LMWH with catheter — contraindicated
• Restart LMWH: 4–24 hours after catheter removal (depending on dose)

---

3.4 Fondaparinux (Indirect Xa Inhibitor)

• Half-life: 17–21 hours (longer in renal impairment)
• Very limited data — neuraxial technique acceptable only if:
  1. Single-needle atraumatic pass
  2. No indwelling neuraxial catheter
• Pre-block: Discontinue ≥ 36–42 hours before (dependent on renal function)
• No reversal agent available

---

3.5 Direct Oral Anticoagulants (DOACs)

General ASRA 5th Edition Principle for DOACs:

• Therapeutic dosing: 5 half-lives before neuraxial block (≈97% elimination)
• Prophylactic/low dosing: 2 half-lives before neuraxial block
• Acceptable drug level: < 30 ng/mL or anti-Xa activity ≤ 0.1 IU/mL (calibrated assay) — allows block earlier than time-based intervals
• Post-block restart: 6 hours after needle/catheter removal (regional guidelines); 24 hours (pain procedure guidelines)

3.5.1 Rivaroxaban (Factor Xa Inhibitor)

• Catheter removal: 6 hours before first post-op dose
• If dose inadvertently given with catheter in situ: wait 22–26 hours before removal OR check calibrated anti-Xa

3.5.2 Apixaban (Factor Xa Inhibitor)

• If dose inadvertently given with catheter in situ: wait 26–30 hours before removal

3.5.3 Edoxaban (Factor Xa Inhibitor)

• If dose given with catheter in situ: wait 20–28 hours before removal OR check calibrated anti-Xa

3.5.4 Betrixaban (Factor Xa Inhibitor)

• Pre-block: Discontinue ≥ 3 days (72 hours) before
• Contraindicated if CrCl < 30 mL/min
• Catheter removal: ≥ 5 hours before first post-op dose
• If inadvertent dose with catheter in situ: 72 hours before removal

3.5.5 Dabigatran (Direct Thrombin Inhibitor — DTI)

• Renal excretion: > 80% — dose interval is highly renal-dependent

• Monitor with thrombin time (TT) or ecarin clotting time (ECT) — NOT aPTT (unreliable)
• Contraindicated with indwelling neuraxial catheter
• Catheter removal: 6 hours before re-dosing

---

3.6 Antiplatelet Agents

NSAIDs / Aspirin (COX inhibitors)

• NSAIDs alone do NOT contraindicate neuraxial block
• Aspirin alone does NOT contraindicate neuraxial block
• Concern arises with combination therapy (aspirin + LMWH; aspirin + warfarin)
• Aspirin is NOT stopped before neuraxial block in most scenarios

Thienopyridines (P2Y12 inhibitors — irreversible)

• Restart: Non-loading dose can be given immediately after block/catheter removal
• With indwelling catheter: clopidogrel/ticlopidine from 24 h postoperatively (no loading dose); catheter use limited to 1–2 days

Non-thienopyridines (P2Y12 inhibitors — reversible)

GP IIb/IIIa Inhibitors

• Contraindicated for neuraxial procedures; discontinue:
  • Eptifibatide / Tirofiban: 8 hours before
  • Abciximab: 48 hours before

Cilostazol

• Discontinue 48 hours before CNB

---

3.7 Fibrinolytic / Thrombolytic Agents (e.g., tPA, streptokinase)

• Neuraxial block contraindicated within 10 days of fibrinolytic/thrombolytic therapy
• Monitor fibrinogen levels (guides timing)
• No established safe interval — avoid neuraxial techniques whenever possible
• If accidentally given with catheter in situ: do not remove catheter; measure fibrinogen every 2 hours; remove catheter only when fibrinogen normalizes

---

3.8 Herbal Medications

• Alone, herbal medications do NOT mandate avoidance of neuraxial block; the concern is with concurrent anticoagulant use

---

4. SPINAL HEMATOMA — DIAGNOSIS & MANAGEMENT

Risk Factors

• Elderly patients (especially women)
• Renal impairment (reduced drug clearance)
• Traumatic/multiple needle passes
• Indwelling neuraxial catheter + anticoagulation
• Combination anticoagulant/antiplatelet therapy
• Spinal/vertebral abnormalities

Clinical Features

• Severe, localized back pain (may be absent in 50%)
• Progressive lower limb weakness and sensory loss
• Bladder and bowel dysfunction (urinary retention is often the first sign)
• Signs evolve over hours; can progress to complete paraplegia

Management

1. Urgent MRI spine (investigation of choice)
2. Neurosurgical consultation immediately
3. Surgical decompression (laminectomy) within 8 hours of onset for best neurological recovery
4. Prognosis: good recovery if decompressed early; poor if delayed > 12 hours

---

5. SUMMARY TABLE — PRE-BLOCK INTERVALS

---

6. MONITORING COAGULATION (Lab Tests)

Important: Uncalibrated or heparin-calibrated anti-Xa assays cannot predict DOAC drug levels accurately.

---

7. SPECIAL POPULATIONS

Obstetric Patients

• Same intervals as non-pregnant population apply for UFH and LMWH
• Risk of SEH is lower in obstetrics than in surgical patients
• Platelet count should be ≥ 80,000/mm³ for neuraxial block (ASRA)
• Anticoagulant therapy: plan neuraxial analgesia timing prospectively from 36 weeks gestation

Elderly / Renal Impairment

• CrCl must be checked before LMWH and DOAC use
• Longer drug-free intervals required for renally cleared agents (LMWH, dabigatran, betrixaban)
• CrCl < 30 mL/min: dabigatran and betrixaban neuraxial block contraindicated

Dual Antiplatelet Therapy (DAPT)

• Neuraxial block generally avoided on DAPT
• If clinically necessary: consult cardiologist, plan around least-risky time window post-stenting

---

8. GRADING OF EVIDENCE (ASRA)

• Grade 1A: Strong recommendation, high-quality evidence (IV heparin protocols)
• Grade 1B: Strong recommendation, moderate-quality evidence
• Grade 1C: Strong recommendation, low-quality evidence (most DOAC intervals)
• Grade 2C: Weak recommendation, low-quality evidence (fondaparinux)

---

9. EXAM HIGH-YIELD POINTS

1. Spinal hematoma is rare (~1 in 150,000 epidurals) but catastrophic; ASRA guidelines aim to minimize this risk.
2. LMWH was the catalyst for modern ASRA guidelines (1993 North America surge in SEH cases).
3. 5 half-lives principle (therapeutic) vs. 2 half-lives (prophylactic) for DOAC clearance.
4. Dabigatran — most renal-dependent DOAC; up to 5 days hold needed; monitor with TT/ECT NOT aPTT.
5. Warfarin — INR must be normal (≤ 1.4) before block; INR < 1.5 for catheter removal.
6. Fibrinolytics — absolute avoidance of neuraxial block within 10 days; if catheter in situ, do NOT remove until fibrinogen normalizes.
7. Aspirin alone = no contraindication to neuraxial block.
8. Clopidogrel — 5–7 days; ticlopidine — 10 days.
9. Calibrated anti-Xa < 30 ng/mL allows earlier neuraxial block with DOACs than time-based intervals.
10. SEH decompression within 8 hours = best prognosis.

---

REFERENCES

• ASRA Pain Medicine Evidence-Based Guidelines (5th Edition, 2022/2025) — Horlocker TT et al., Reg Anesth Pain Med
• Miller's Anesthesia, 10th Edition — Chapter 77 (Risks with Epidural Analgesia; Anticoagulation), pp. 11742–11744
• Morgan & Mikhail's Clinical Anesthesiology, 7th Edition — Chapter 45 (Oral Anticoagulants), p. 1809
• Mulholland & Greenfield's Surgery, 7th Edition — Chapter 13 (Risks with Regional Techniques in Anticoagulated Patients)
• Schieber MR et al. "Influence of antithrombotic medication on size and neurological outcome of spinal epidural hematoma after neuraxial anesthesia." Reg Anesth Pain Med. 2025 [PMID: 38129095]
• Suleiman A et al. "Direct oral anticoagulant management for neuraxial anaesthesia and deep peripheral nerve blocks." Br J Anaesth. 2025 [PMID: 41073233]

---